Reference

Valacyclovir for the treatment of genital herpes

All Rights Reserved. Valacyclovir for the treatment of genital herpes. Brantley, Julie S.; Hicks, Lindsey; Sra, Karan; Tyring, Stephen K. ( Department of Dermatology, The University of Texas Medical Branch, Galveston, TX 77555, USA). Expert Review of Anti-Infective Therapy, 4(3), 367-376 (English) 2006 Future Drugs Ltd. CODEN: ERATCK. ISSN: 1478-7210. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Genital herpes is the most prevalent sexually transmitted infection in the USA. While sometimes mild in severity, it can be a distressing and painful chronic condition. Likewise, herpes labialis and herpes zoster can be both phys. and psychol. painful. While there is no cure for these conditions, treatment to alleviate symptoms, suppress recurrences and reduce transmission has been drastically improved over the past 20 years with the use of guanine nucleoside antivirals, such as valacyclovir hydrochloride (Valtrex, GlaxoSmithKline) the highly bioavailable prodrug of acyclovir (Zovirax, GlaxoSmithKline), and famciclovir (Famvir, Novartis), a highly bioavailable prodrug of penciclovir (Denavir, Novartis). Clin. trials involving approx. 10,000 patients (including patients from nongenital herpes studies, such as herpes zoster) have assessed the safety and efficacy of valacyclovir in the treatment of initial genital herpes outbreaks, episodic treatment of recurrent episodes and daily suppressive therapy. It was shown that valacyclovir has similar efficacy to acyclovir in the episodic and suppressive treatment of genital herpes. 124832-27-5 is also in the experiment. Valacyclovir is the only antiviral drug approved for a once-daily dose of suppressive therapy for genital herpes, as well as the only antiviral drug US FDA approved for a 3-day regimen of episodic treatment of recurrent genital herpes. In addn., valacyclovir is also indicated in the redn. of the sexual transmission of herpes simplex virus infection and for the treatment of herpes labialis. In herpes zoster, valacyclovir is more effective than acyclovir or placebo (and as equally effective as famciclovir) in shortening the length and severity of herpes zoster-assocd. pain and postherpetic neuralgia. Valacyclovir has an acceptable safety profile in patients with herpes simplex and herpes zoster. The less frequent dosing regimen makes it an attractive option in the treatment of genital herpes and other viral infections, and may contribute to increased patient adherence to therapy. .

Antiviral agents with antihyperproliferative activity for the treatment of psoriasis

Antiviral agents with antihyperproliferative activity for the treatment of psoriasis. Rowjee, Zehra (USA ). PCT Int. Appl. WO 2004014385 A1 19 Feb 2004,26 pp.Some commonly used reagents like 124832-26-4 and 124832-27-5 are used in this experiment. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-522. APPLICATION: WO 2003-US25142 11 Aug 2003. PRIORITY: US 2002-PV402525 9 Aug 2002. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 The invention discloses the prevention of psoriatic-related disorders via administration of antiviral agents or combination of antiviral agents that possess antihyperproliferative pharmacol. activity. Agents of the invention include e.g. valacyclovir. .